Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.

Cannabis has gone through a breeding bottleneck with prohibition and many silent chemotypes we believe will be found in the genomics of existing strains.

Stay scientific and don’ t be influenced by 30 year old stigmas Better Cannabis regulation is needed. FDA trials on complex drug cocktails are expensive making it unlikely to be a pharmaceutical priority given the generic being ever present.

4.
Social and political considerations Over 1M US citizens imprisoned every year for Cannabis. 7.8M citizens imprisoned in 10 years $50B/year in Prisons. Private prisons growing 17%/year. 25% of Global prisoners in the USRate of prescription drug overdoses per 100K- source CDC

7.
Human variation of the Receptors Are there populations with mutations in CB1, CB2, “CB3“ which may require custom dosages of Cannabinoids?

8.
Over 85 Cannabinoids discovered Cannabis has gone through a breeding bottleneck with prohibition and many silent chemotypes we believe will be found in the genomics of existing strains.http://en.wikipedia.org/wiki/Cannabinoids What are the genetic pathways? Which enzymes have variants in these pathways? Are there extinct synthases in the genome which can be discovered/recovered? Terpenoids?

29.
What markets are enabled with this? Understanding Cannabichromene requires Schedule I licenses (time) and is a longer term project. Armed with the genome we can design QPCR assays to quantitate Cannabinoid RNA and Mold for better labeling. Courtagen also has the potential for Q400 ELISA assays for Pesticides and Mold Medical Cannabis Industry needs better labeling and POC assays are required to manage diversion concerns inherit in centralized testing labs. Can we sequence patients to better understand cannabinoids and metabolic disease?